Roche wa­gers $180M in quick cash on a can­di­date for best-in-class tu­mor tar­get­ing drug

Roche has signed a $1.3 bil­lion deal to gain world­wide rights to an ex­per­i­men­tal can­cer drug chief deal­mak­er James Sabry be­lieves can play a big role in fight­ing mul­ti­ple can­cers.

The phar­ma gi­ant is putting up $125 mil­lion of that in an up­front, along with $55 mil­lion in near-term re­wards for a big piece of the po­ten­tial ac­tion on ca­mon­sert­ib (RP-3500), an oral small mol­e­cule in­hibitor of ATR, or Atax­ia-Telang­iec­ta­sia and Rad3-re­lat­ed pro­tein ki­nase, in de­vel­op­ment at Re­pare Ther­a­peu­tics $RP­TX.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER